explore -WSS

explore

author：Wikipedia 2025-09-03 14:37:19 - browse：97

Two boxes of Humira and a Humira pen on the side — first opinion coverage from STAT — David J. Phillip/AP

It’s been one year since the launch of the first adalimumab biosimilar for Humira in the United States, which was followed by eight additional adalimumab biosimilar launches. These nine FDA-approved products offer lower-cost alternatives to the world’s bestselling drug, Humira, used to treat rheumatoid arthritis, Crohn’s disease, and other autoimmune disorders. This made 2023 a watershed year for millions of U.S. patients paying too much for their necessary medications.

But so far, that vision hasn’t come to fruition, because policymakers haven’t taken the action necessary to be sure these lower-cost products are accessible for patients. If they fail to act, the U.S. health care system could lose up to $133 billion in savings and leave patients without access to the medicines they need.

Biosimilars are safe and effective treatments referencing biologic drugs. They are market disruptors, forcing lower prices for biologic medicines. The cost savings from reference biologic products begins almost immediately when biosimilars enter the market and continues over time.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： H5N1 bird flu: what we're starting to learn about infection in cows

hotspot

WSS

David Ricks of Eli Lilly: best biopharma CEO of 2023

H5N1 communication has been strictly for the birds

Can sheer will power keep patients alive in their dying hours?

Why health records don't always know when patients are dead

Google says AlphaFold 3 can map a vast universe of biomolecules

Prime Medicine, Myeloid Therapeutics clash over genome

leisure time

explore

knowledge

Continuity nursing helped my family in our darkest PICU moments

Editas, Vertex strike deal on CRISPR

Sports medicine is finally prioritizing gender equality

Hospitals owned by private equity see complications spike 25%

Supreme Court strikes down use of affirmative action

Advocates call out 'SNL' over stereotypes, errors in sickle cell skit

Activists slam private health insurers over coverage restrictions

Researchers on aging grapple with how to calculate biological age

Moonlake's readout produced a cash windfall. Risks remain

Prime Medicine, Myeloid Therapeutics clash over genome

leisure time

Steward Health Care files for bankruptcy

Three trends to watch in biotech in 2024

Drinking less cuts risk of oral cavity, esophageal cancer: Report

Telehealth startups turn to complex chronic diseases

Steward Health Care files for bankruptcy

SNAP should offer more nutrition education

explore

hotspot

focus

focus